Brokerages expect Arsanis Inc (NASDAQ:ASNS) to report earnings per share (EPS) of ($0.49) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Arsanis’ earnings. The firm is expected to announce its next earnings results on Monday, November 12th.

On average, analysts expect that Arsanis will report full year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.46) to ($2.46). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.54) per share, with EPS estimates ranging from ($3.56) to ($1.51). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Arsanis.

Arsanis (NASDAQ:ASNS) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03).

Several brokerages recently issued reports on ASNS. Zacks Investment Research upgraded Arsanis from a “sell” rating to a “hold” rating in a research note on Thursday, May 24th. Citigroup cut Arsanis from a “buy” rating to a “neutral” rating in a research note on Monday, July 9th. Piper Jaffray Companies cut Arsanis from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $26.00 price target on shares of Arsanis in a research note on Thursday, June 28th. Finally, Cowen downgraded shares of Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $14.88.

Shares of ASNS stock traded down $0.09 during trading on Friday, hitting $1.78. The company had a trading volume of 91,200 shares, compared to its average volume of 77,390. The company has a current ratio of 7.38, a quick ratio of 7.38 and a debt-to-equity ratio of 0.20. The stock has a market cap of $32.31 million and a P/E ratio of -0.11. Arsanis has a one year low of $1.71 and a one year high of $28.69.

Several large investors have recently made changes to their positions in the company. Granahan Investment Management Inc. MA acquired a new position in shares of Arsanis during the second quarter worth $365,000. BlackRock Inc. increased its holdings in shares of Arsanis by 27.1% during the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock worth $812,000 after buying an additional 47,777 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of Arsanis during the first quarter worth $162,000. New York State Common Retirement Fund acquired a new position in shares of Arsanis during the first quarter worth $114,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Arsanis by 6.4% during the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock worth $5,663,000 after buying an additional 14,819 shares in the last quarter. Institutional investors own 71.63% of the company’s stock.

About Arsanis

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Arsanis (ASNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arsanis (NASDAQ:ASNS)

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.